Topoisomerase IIα gene expression in childhood acute lymphoblastic leukemia

Keyphrases

• Gene Expression 100%
• Childhood Acute Lymphoblastic Leukemia 100%
• Topoisomerase II 100%
• Daunorubicin 50%
• Relapsed or Refractory Acute Myeloid Leukemia 40%
• Leukemia 30%
• In Vitro Cytotoxicity 30%
• Anthracyclines 10%
• Acute Lymphoblastic Leukemia 10%
• Initial Diagnosis 10%
• Acute Lymphoblastic Leukemia Cells 10%
• Topoisomerase Inhibitors 10%
• Sigma Phase 10%
• Cell Cycle Distribution 10%
• Chemosensitive 10%
• RNase Protection 10%
• Multidrug Resistance 10%
• Long-term Clinical Outcome 10%
• In Vitro Resistance 10%
• MTT Assay 10%
• Epipodophyllotoxin 10%
• Teniposide 10%
• Lung Cancer Cell Lines 10%
• Inter-patient 10%
• DNA Flow Cytometry 10%
• Intracellular Targets 10%
• Non-small Cell Lung Cancer Cells 10%
• G2M Phase 10%
• Activity Study 10%

Medicine and Dentistry

• Acute Lymphoblastic Leukemia 100%
• Gene Expression 100%
• DNA Topoisomerase (ATP Hydrolysing) 100%
• In Vitro 50%
• Liposomal Daunorubicin 50%
• Cytotoxicity 30%
• Teniposide 30%
• Cell Line 10%
• Anthracycline 10%
• Leukemia 10%
• Flow Cytometry 10%
• Leukemia Cell 10%
• Cell Cycle 10%
• Multidrug Resistance 10%
• MTT Assay 10%
• Epipodophyllotoxin 10%
• Lung Cancer Cell Line 10%
• Small Cell Lung Cancer 10%
• Gyrase Inhibitor 10%
• Ribonuclease Protection Assay 10%